Front Row Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Front Row Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9	Closed	-$2K	–	1026
2019 Q2	$2K	Hold	9	–	–	﹤0.01%	878
2019 Q1	$2K	Hold	9	–	–	﹤0.01%	876
2018 Q4	$1K	Hold	9	–	–	﹤0.01%	989
2018 Q3	$1	Hold	9	–	–	﹤0.01%	948
2018 Q2	$2	Buy	+9	New	+$1.4K	﹤0.01%	880

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Front Row Advisors's VRTX Position: Q3 2019 in Review

Front Row Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2019, closing a stake of 9 shares — an estimated $2K sold.

Front Row Advisors first reported a position in VRTX in Q2 2018 and held it in 5 quarters. The position peaked at $2K in Q2 2019. 707 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Front Row Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Front Row Advisors sold 9 Vertex Pharmaceuticals shares in Q3 2019, an estimated $2K.
Front Row Advisors first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Front Row Advisors's Vertex Pharmaceuticals position peaked at $2K in Q2 2019.
707 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Front Row Advisors's 13F filing for Q3 2019, filed 8 Nov 2019.